vTv Therapeutics
VTVT
45 hedge funds and large institutions have $60.5M invested in vTv Therapeutics in 2026 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
29% more funds holding
Funds holding: 35 → 45 (+10)
3.04% more ownership
Funds ownership: 37.76% → 40.8% (+3%)
3% more capital invested
Capital invested by funds: $59M → $60.5M (+$1.52M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.2M |
| 2 |
ACM
Aisling Capital Management
New York
|
+$1.73M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$908K |
| 4 |
Renaissance Technologies
New York
|
+$605K |
| 5 |
Jane Street
New York
|
+$475K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$1.89M |
| 2 |
6CM
683 Capital Management
New York
|
-$635K |
| 3 |
Goldman Sachs
New York
|
-$529K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$501K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$414K |
VTVT Hedge Fund Activity: Q2 2026 in Review
45 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2026, worth a combined $60.5M — up 2.6% from $59M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new VTVT positions and 6 closed out — a net gain of 11 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.2M. The largest seller was Trails Edge Capital Partners, cutting an estimated $1.89M.
- 45 institutional investors held vTv Therapeutics (VTVT) as of Q2 2026, up from 35 in Q1 2026.
- Funds reported $60.5M of vTv Therapeutics stock for Q2 2026, up 2.6% quarter-over-quarter.
- 17 funds opened new vTv Therapeutics positions in Q2 2026 and 6 closed out, a net change of +11 holders.
- The largest vTv Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $2.2M added.
- The largest vTv Therapeutics seller in Q2 2026 was Trails Edge Capital Partners, an estimated $1.89M sold.
Based on aggregated 13F filings for Q2 2026.